Shares of Hims & Hers Health Inc. (HIMS) surged 5.31% on Thursday, outperforming the broader market during the intraday trading session. The telehealth company's stock rallied amidst attention and buzz surrounding its provocative Super Bowl commercial criticizing weight-loss drug makers and the U.S. healthcare system.
While the controversial ad has prompted backlash from Senators Richard Durbin and Roger Marshall, who have requested an FDA investigation into potential misleading claims, it has also generated significant publicity for the company. Despite the controversy, Hims & Hers remains a highly rated stock in its industry group, with strong rankings for its Composite Rating, EPS Rating, and Relative Strength Rating.
Investors appear to be anticipating positive news from the company's upcoming earnings report scheduled for February 24th, which could provide further insight into its performance and outlook. The stock's rally highlights the market's interest in Hims & Hers and its ability to capitalize on the attention generated by its bold marketing strategy.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。